The median survival for mesothelioma is 12 to 21 months depending on type and stage, with a 5-year survival rate of approximately 12% across all stages. However, prognosis varies significantly based on the type of mesothelioma, stage at diagnosis, cell type, patient age and health, and treatment approach. Peritoneal mesothelioma patients treated with HIPEC have achieved 5-year survival rates of 50–60%, and new treatments — particularly immunotherapy — continue to improve outcomes.
Survival by Type
| Type | Median Survival | 5-Year Rate | Key Factor |
|---|---|---|---|
| Pleural | 12–21 months | ~10% | Stage at diagnosis is the strongest predictor |
| Peritoneal (with HIPEC) | Varies widely | 50–60% | HIPEC treatment dramatically improves outcomes |
| Pericardial | ~6 months | Very limited data | Often diagnosed late or at autopsy |
| Testicular | Varies | ~50% | Rarest form but most favorable prognosis |
Survival by Stage (Pleural Mesothelioma)
| Stage | Median Survival | Treatment Landscape |
|---|---|---|
| Stage I | 21+ months | Most options available: surgery, chemo, immuno, radiation |
| Stage II | ~19 months | Surgery often still possible; multimodal approach |
| Stage III | ~16 months | Limited surgery; chemo + immunotherapy primary |
| Stage IV | ~12 months | Palliative care; systemic treatment; clinical trials |
Factors That Improve Prognosis
- Earlier stage at diagnosis — more treatment options and better response rates
- Epithelioid cell type — most responsive to treatment; accounts for 50–70% of cases
- Younger age and good overall health — better ability to tolerate aggressive treatment
- Access to specialized treatment centers — where oncologists have mesothelioma experience
- Multimodal treatment approach — combining surgery, chemotherapy, and immunotherapy
- Clinical trial participation — access to emerging treatments
Treatment Advances Are Changing Outcomes
While mesothelioma remains a serious diagnosis, outcomes are improving. The 2020 FDA approval of immunotherapy (nivolumab + ipilimumab) provided the first new treatment option in 16 years. HIPEC has transformed peritoneal mesothelioma from a near-universally fatal diagnosis to one where long-term survival is achievable. Ongoing clinical trials in gene therapy, CAR-T cells, and tumor-treating fields continue to push the boundaries of what is possible.